Looking to the future, emerging life sciences technologies will drive the industry, enabling a new wave of scientific understanding and therapies developed for patients with conditions once thought impossible to treat. With an eye toward the future of life sciences technology, BroadOak has built a team and a network of key opinion leaders with the experience and knowledge in Cell and Gene therapy, Single Cell, Bioprocess, and Life Sciences Software. BroadOak executives serve on the boards of leading life sciences companies and organizations, including MD Bio, Science and Medicine Group, and Slone Partners. As one of the most active investors in the space, BroadOak combines financial expertise and deep knowledge of the life sciences industry to offer investment companies and advisory clients a compelling value proposition.
Learn more about BroadOak’s most recent industry engagement:
Once a year, we welcome founders, investors, and stakeholders for several days to discuss the latest trends and developments in the life sciences tools, diagnostics, and biopharma services industries. Unstructured time is built in so entrepreneurs, investors, and experts can make valuable connections. Our eight Investor Day was held in February of 2025.
BroadOak is a founding sponsor of BioTools Innovator, the world’s premier nonprofit accelerator and competition for life science tools and diagnostic companies. Managing Director Austin Duke and Principal Dan Friedman represented BroadOak at the event. Miltenyi graciously hosted BioTools Innovator’s first International Pitch Event in Cologne, Germany. Hundreds of companies applied to receive mentorship and funding from leading investors.
Advanced Therapies Week is an opportunity to connect with people and organizations helping bring cell and gene therapies to patients. At the 2025 event, Principal Dan Friedman spoke on the panel: Investing in Tools Services and Propelling the CGT Ecosystem.
BroadOak knows the life sciences tools and services industry inside and out. From start to finish, our relationship has been a true partnership.
Tom Hiddemann
Managing Director | Antibodies-Online
We invest in and advise life sciences companies with a focus on Cell and Gene Therapy, Single Cell Genomics, and Life Sciences Software.
Stay connected
Partner with BroadOak